Major Depressive Disorder Among Children and Adolescents
Abstract
Depression among youths remains a public health concern, particularly because only a fraction of affected youths receive treatment. To obtain treatment, youths with depression must first be identified so that early intervention can occur. Furthermore, investigation of both more effective pharmacological agents and more widespread accessibility of cognitive-behavioral interventions are necessary. To address unmet needs in the identification and treatment of depression among youths, clinical counseling programs are being developed in primary care clinics and in schools to identify and treat depressive symptoms or milder major depressive disorder and have shown promising outcomes thus far in reducing depression and increasing quality of life.
Major depressive disorder is an enduring and impairing condition that can affect children as young as preschoolers and increases in frequency with age (1, 2). The clinical presentation in youths may be characterized by irritable and angry mood rather than persistent sadness, and it may include a lack of attaining expected weight rather than losing weight (2). Early onset of major depressive disorder is associated with a greater number of episodes over time, higher risk of suicidal thoughts, more comorbid disorders, and decreased contribution of genetic factors (1–3). Overall heritability of major depressive disorder is estimated to be approximately 35%, with increasing genetic influence proportional to age of onset (3). The impact of adverse and traumatic experiences on the development of major depressive disorder in youths is mediated by gene-environment interactions (i.e., the product of an individual’s genetic vulnerability and the adversity experienced) (1). Major depressive disorder in children and adolescents may lead to persisting social, emotional, and cognitive impairments, making early identification, treatment, and prevention a high priority (4, 5).
Definition
DSM-5 (6) defines major depressive disorder as an episodic condition characterized by depressed mood (or irritable mood of children and adolescents) and/or loss of interest or pleasure most of the day nearly every day for 2 weeks, as well as the presence of at least four additional symptoms during the same period. Symptoms include weight loss or gain, insomnia or hypersomnia nearly every day, psychomotor agitation or retardation, daily fatigue or loss of energy, feelings of worthlessness or excessive guilt, diminished ability to think or concentrate, or recurrent thoughts of death or suicidal thoughts (6)
Specifiers for major depressive disorder in DSM-5 (6) include mild, moderate, severe, with psychotic features, in partial remission, in full remission, and unspecified. A change in DSM-5 is that a diagnosis of major depressive disorder may be applied when criteria are met even less than 2 months after the loss of a loved one.
Epidemiology
Depressive disorders are reported in up to 2% of preschoolers and prepubertal children (7, 8), occurring equally with boys and girls (9). In adolescence, however, not only do the rates of major depressive disorder increase dramatically, but girls are affected twice as often as boys (10).
Data from the National Comorbidity Survey–Adolescent Supplement (NCS-A) (11, 12) showed a lifetime prevalence of major depressive disorder of 11% and a 12-month rate of 7.5% among individuals aged 13–18 years. The one-fourth of adolescents who experience a more severe form of major depressive disorder exhibit two to five times more impairment and higher rates of suicidal ideation and behaviors (13).
Etiology: Gene-Environment Interactions
Evidence suggests that specific gene variants contribute to depression among youths not only by directly increasing risk but also by influencing an individual’s sensitivity to environmental experiences such as adversity (1, 14–16). Evidence from adoption studies indicates that psychosocial mechanisms contribute to depression among youths as well, given the findings of increased rates of depression in biologically unrelated adopted children of depressed mothers compared with children adopted by nondepressed mothers (4, 17).
Gene-environment researchers are investigating how genetic variants influence an individual’s sensitivity not only to adverse events but also to positive environmental experiences, which may contribute to resilience to depression and other psychiatric disorders (1, 10, 18). For example, genetic factors including high intelligence, as well as positive experiences leading to increased emotion-regulation capacity and coping mechanisms, have been reported to protect against depression of high-risk adolescents (10, 18).
Much research has focused on a variant in the serotonin transporter gene (5-HTTLPR), which increases the risk for depression, particularly for female individuals exposed to early adverse life events (10, 15). Children exposed to early maltreatment who carry the short alleles of the 5-HTTLPR gene appear to be at greater risk for depression later in adolescence than those with the long 5-HTTLPR allele (1, 15). Although it appears that 5-HTTLPR variants influence amygdala reactivity independent of early maltreatment (16), certain 5-HTTLPR variants are believed to influence both susceptibility and resilience to depression in the face of either negative or positive experiences (1, 19). Therefore, positive family and peer relationships may mitigate the severity of depression or serve as protective factors for some individuals (10, 18, 19).
Differential Diagnosis and Comorbidity
The differential diagnosis of major depressive disorder among children includes dysthymic disorder, disruptive mood dysregulation disorder, oppositional defiant disorder, adjustment disorder, bipolar disorder, and, in rare cases, schizophrenia (2). Diagnosis of major depressive disorder is also complicated by the prominence of comorbid disorders (2, 13). The NCS-A reported that 63.7% of adolescents with major depressive disorder met criteria for another psychiatric disorder within a year, particularly anxiety and behavioral disorders, including attention-deficit hyperactivity disorder and substance use disorders (13).
Treatment
There is an increasing body of published literature on evidence-based psychotherapeutic and pharmacological treatments alone and in combination for major depressive disorder among youths; however, best-practice recommendations still include expert clinical consensus (2, 4, 20). Cognitive-behavioral therapy (CBT) has the most evidence of efficacy among youths with major depressive disorder, with trials with large sample sizes and consistent moderate effect sizes (2, 4, 21). Interpersonal therapy (IPT) is supported by some evidence from three randomized controlled trials (22, 23) and from one randomized but uncontrolled study comparing IPT with a form of CBT with patients with early-onset chronic depression (24).
The update of the Texas Children’s Medication Algorithm Project (20) recommends that effective interventions for milder forms of depression among youths without risk of suicidal thoughts or behaviors include supportive, psychodynamic, family therapy, and psychoeducation.
For youths with moderate to more serious forms of major depressive disorder, the decision to treat with selective serotonin reuptake inhibitors (SSRIs), CBT, or both involves consideration of the severity of the depression, the immediate risk of suicidal behavior, family history of major depressive disorder and treatment responses, and whether the depression is recurrent (2, 4, 10, 20).
SSRIs are the first line of evidence-based pharmacological treatment for depression, and a meta-analysis showed an average response rate of 60% for SSRIs and 49% for placebo (2, 4, 10). Efficacious SSRIs include fluoxetine, sertraline, citalopram, paroxetine, and venlafaxine (2). High rates of placebo response for major depressive disorder among youths have made it more difficult to show efficacy of medications (2, 4, 10). The U.S. Food and Drug Administration has approved fluoxetine and escitalopram (for patients ages >8 and >12 years, respectively) in the acute and maintenance treatment of depression (2).
Concerns regarding the increased rates of suicidal thoughts, but not completed suicide, among adolescents treated with SSRIs in clinical trials compared with placebo have been mitigated by a meta-analysis indicating that the benefits of SSRI treatments far outweigh the risks of untreated depression (2, 10, 25). A meta-analysis of clinical trials for adolescent depression with newer-generation antidepressants (26) showed no advantage over SSRIs; therefore, fluoxetine, sertraline, and other SSRIs are still first-line treatments (2, 4, 10). To our knowledge, there are no controlled trials of bupropion or mirtazapine with children or adolescents, and trials have not shown efficacy of tricyclic antidepressants nefazodone or duloxetine in the treatment of major depressive disorder in youth (2).
Several large, multisite, randomized controlled studies have investigated the efficacy of SSRI antidepressants, CBT, and the combination CBT and SSRIs for youths with moderate to severe depression.
The Treatment for Adolescents With Depression Study (TADS) (27, 28) consisted of a 12-week trial in 439 individuals (ages 12–17 years) with major depressive disorder. Participants were randomly assigned to one of four treatment groups: fluoxetine alone (10–40 mg/day), CBT alone, CBT with fluoxetine (10–40 mg/day), or placebo (equivalent to 10–40 mg/day). The TADS results at 12 weeks, using the Children’s Depression Rating Scale–Revised (29), showed the combination of CBT with fluoxetine to be statistically significantly more efficacious compared with placebo and superior to fluoxetine alone and CBT alone (27). Fluoxetine alone was found to be superior to CBT alone at 12 weeks (27) (Table 1).
| TADS Treatment Condition | N | Response Rate (%) |
|---|---|---|
| Fluoxetine alone (10–40 mg/day) | 109 | 61 |
| CBT alone | 111 | 43 |
| CBT with fluoxetine (10–40 mg/day) | 111 | 71 |
| Placebo (equivalent to 10–40 mg/day) | 112 | 35 |
Using the improvement scale of the Clinical Global Impressions Scale (CGI-I) (30), both of the fluoxetine conditions were statistically significantly superior to the CBT and the placebo conditions (27).Predictors of response in the TADS study included younger age, less chronic depression or hopelessness, less suicidal ideation, and greater expectations for improvement (31). Combined CBT with fluoxetine was more effective than fluoxetine alone only for adolescents with mild or moderate depression and for those exhibiting cognitive distortions, but not for those with more severe depression (31). However, using intention-to-treat analyses, treatments were similarly efficacious on follow-up of active TADS treatment groups at 18 and 36 weeks (28) (Table 2). TADS longitudinal data also showed that adolescents treated with combination treatment or CBT alone were less likely to experience suicidal ideation than those treated with fluoxetine alone (28, 32).
| TADS Treatment Condition | N | Much Improved | ||
|---|---|---|---|---|
| 12 Weeks | 18 Weeks | 36 Weeks | ||
| Fluoxetine alone | 109 | 62 | 69 | 81 |
| CBT alone | 111 | 48 | 65 | 81 |
| CBT with fluoxetine | 107 | 73 | 85 | 86 |
a
Intent-to-treat analysis. Data are given in percentages unless indicated otherwise. CBT, cognitive-behavioral therapy; TADS, Treatment for Adolescents With Depression Study (28).
The second large study, the Adolescent Depression Antidepressant and Psychotherapy Trial (ADAPT) (33), was conducted in the United Kingdom. ADAPT was a 12-week randomized controlled (unblinded) trial with youths ages 11–17 who had major depressive disorder, followed by a 16-week maintenance phase. Fluoxetine was the primary SSRI chosen. ADAPT (33), in contrast with the TADS study (24), included youths with active suicidality, depressive psychotic symptoms, and conduct disorder (33). All ADAPT adolescents received “routine specialist clinical care,” which focused on psychoeducation and attention to family and peer conflicts. Participants were divided into two treatment groups (33, 34): SSRI and routine specialist clinical care (N=103), and SSRI and routine specialist clinical care and CBT (N=105). The main outcome measure was a change in the score on the Health of the Nation Outcome Scales (35).
Response rates using odds ratios for CGI-I scores for the two conditions at 6, 12, and 28 weeks are shown in Table 3. The ADAPT researchers concluded that routine specialist clinical care plus SSRI treatment was equally efficacious with or without the addition of CBT (33, 34). A weakness of ADAPT was the absence of a placebo group; however, this study’s strength was the inclusion of adolescents with comorbidity, suicidal ideation, and psychosis (33, 34)
| SSRI Plus Routine Care | SSRI Plus Routine Care Plus CBT | |||
|---|---|---|---|---|
| Time point | N | % | N | % |
| 6 weeks | 35 | 36 | 34 | 35 |
| 12 weeks | 44 | 44 | 42 | 42 |
| 28 weeks | 57 | 61 | 52 | 53 |
a
ADAPT, Adolescent Depression Antidepressant and Psychotherapy Trial (34); CBT, cognitive-behavioral therapy; SSRI, selective serotonin reuptake inhibitor.
At 28 weeks, 23% of ADAPT participants remained depressed (33). Predictors of poor response included the severity of depression, suicidal ideation at study entry, comorbid obsessive-compulsive disorder at entry, and at least one adverse life event during the follow-up period (36).
In contrast with a lack of increased efficacy found in adding CBT to antidepressants in the most severely depressed adolescents in both the TADS (27) and ADAPT (33) studies, combining CBT with antidepressants proved more efficacious than medication alone in the Treatment of Resistant Depression in Adolescents (TORDIA) study (37).
The TORDIA (37) study was a 12-week randomized controlled trial of 334 adolescents with depression (ages 12−18 years), all of whom had unsuccessful previous SSRI treatment. These adolescents were randomly assigned to one of four treatment groups: switch to a second different SSRI (including fluoxetine, paroxetine, or citalopram 20–40 mg/day), switch to a different SSRI plus CBT, switch to venlafaxine (150–225 mg/day), or switch to venlafaxine plus CBT. Both CBT groups showed better response at week 12 (54.8%) than those without CBT (40.5%). Response rates of TORDIA study completers by group are shown in Table 4.
| SSRI (N=117) | Venlafaxine (N=114) | Medication Only (N=121) | Medication Plus CBT (N=110) | |||||
|---|---|---|---|---|---|---|---|---|
| Outcome Measurement | N | % | N | % | N | % | N | % |
| Overall response rate | 64 | 55 | 65 | 57 | 60 | 57 | 69 | 63 |
| CGI-I | 70 | 59 | 76 | 67 | 72 | 60 | 74 | 67 |
| Change in CDRS-R | 73 | 62 | 69 | 61 | 68 | 56 | 74 | 67 |
The TORDIA study investigators found that 50% of participants who did not respond to a first SSRI treatment responded to a second treatment (37). Evidence also suggests that combination treatment for adolescents with treatment-resistant major depressive disorder may add to prevention of relapse (38).
Approximately 60% of depressed adolescents have responded to their first SSRI trial (25), and one-half of these individuals can be expected to respond to a second SSRI; therefore, after two antidepressant trials, treatment resistance continues to be an issue for 20% of youths with depression (2, 38). Although randomized controlled trials investigating duloxetine in adolescent depression have been negative (possibly owing to the high placebo response), agents such as bupropion or duloxetine may be tried when depression is resistant to treatment with SSRIs. In cases of partial response to SSRIs, augmentation with another antidepressant is considered (20, 38, 39)
Prevention
Prevention strategies often target three high-risk groups: offspring of parents who have had depression, adolescents with subthreshold depressive symptoms, and adolescents with previous episodes of depression (10, 39–45).
A cognitive-behavioral prevention (CBP) program by Clarke et al. (40) and modifications thereof demonstrated a reduction in new episodes, as well as existing depressive symptoms of high-risk youths (41–43). A randomized controlled trial (44) of 316 currently or previously depressed adolescent offspring of parents with past or current depression received either an 8-week group CBP program followed by six monthly continuation sessions or usual care. The CBP intervention consisted of problem solving and cognitive restructuring (44). Over 9 months, those receiving CBP had significant reductions in new episodes and symptoms (21.4%) compared with the usual care group (32.7%) (44, 45). Adolescents who received the CBP had 11% fewer depressive episodes compared with those who received usual care (44).
Long-term follow-up demonstrated positive effects of the CBP intervention for nearly 3 years; however, this finding was predominantly for adolescents whose parents were not depressed when their children entered the study (45, 46). The authors concluded that for optimal prevention of depression among high-risk adolescent offspring, parents may need to be treated before or during the CBP intervention.
Footnote
Dr. Pataki reports no financial relationships with commercial interests. Dr. Carlson reports receipt of research funds from Pfizer Pharmaceuticals.
References
1.
Goodyer IM: Genes, environments and depressions in young people. Arch Dis Child 2015; 100:1064–1069
2.
Wagner KD, Brent DA: Depressive disorders and suicide, in Kaplan & Sadock’s Comprehensive Textbook of Psychiatry, 9th ed. Edited by Sadock BJ, Sadock VA, Ruiz P. Philadelphia, Wolters Kluwer/Lippincott Williams & Wilkins, 2009, pp 3652–3663
3.
Uher R: Gene-environment interactions in severe mental illness. Front Psychiatry 2014; 5:48
4.
Maughan B, Collishaw S, Stringaris A: Depression in childhood and adolescence. J Can Acad Child Adolesc Psychiatry 2013; 22:35–40
5.
Fletcher JM: Adolescent depression: diagnosis, treatment, and educational attainment. Health Econ 2008; 17:1215–1235
6.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington, VA, American Psychiatric Association, 2013
7.
Wichstrøm L, Berg-Nielsen TS, Angold A, et al: Prevalence of psychiatric disorders in preschoolers. J Child Psychol Psychiatry 2012; 53:695–705
8.
Luby JL: Preschool depression: the importance of identification of depression early in development. Curr Dir Psychol Sci 2010; 19:91–95
9.
Egger HL, Angold A: Common emotional and behavioral disorders in preschool children: presentation, nosology, and epidemiology. J Child Psychol Psychiatry 2006; 47:313–337
10.
Thapar A, Collishaw S, Pine DS, et al: Depression in adolescence. Lancet 2012; 379:1056–1067
11.
Merikangas KR, He JP, Burstein M, et al: Lifetime prevalence of mental disorders in US adolescents: results from the National Comorbidity Survey Replication—Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry 2010; 49:980–989
12.
Merikangas K, Avenevoli S, Costello J, et al: National Comorbidity Survey Replication Adolescent Supplement (NCS-A): I. Background and measures. J Am Acad Child Adolesc Psychiatry 2009; 48:367–369
13.
Avenevoli S, Swendsen J, He JP, et al: Major depression in the National Comorbidity Survey–Adolescent Supplement: prevalence, correlates, and treatment. J Am Acad Child Adolesc Psychiatry 2015; 54:37–44.e2
14.
Thapar A, Rice F: Twin studies in pediatric depression. Child Adolesc Psychiatr Clin N Am 2006; 15:869–881, viii
15.
Uher R, McGuffin P: The moderation by the serotonin transporter gene of environmental adversity in the etiology of depression: 2009 update. Mol Psychiatry 2010; 15:18–22
16.
Walsh ND, Dalgleish T, Dunn VJ, et al: 5-HTTLPR-environment interplay and its effects on neural reactivity in adolescents. Neuroimage 2012; 63:1670–1680
17.
Tully EC, Iacono WG, McGue M: An adoption study of parental depression as an environmental liability for adolescent depression and childhood disruptive disorders. Am J Psychiatry 2008; 165:1148–1154
18.
Silk JS, Vanderbilt-Adriance E, Shaw DS, et al: Resilience among children and adolescents at risk for depression: mediation and moderation across social and neurobiological contexts. Dev Psychopathol 2007; 19:841–865
19.
Collishaw S, Pickles A, Messer J, et al: Resilience to adult psychopathology following childhood maltreatment: evidence from a community sample. Child Abuse Negl 2007; 31:211–229
20.
Hughes CW, Emslie GJ, Crismon ML, et al: Texas Children’s Medication Algorithm Project: update from Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:667–686
21.
Arnberg A, Ost LG: CBT for children with depressive symptoms: a meta-analysis. Cogn Behav Ther 2014; 43:275–288
22.
Mufson L, Dorta KP, Wickramaratne P, et al: A randomized effectiveness trial of interpersonal psychotherapy for depressed adolescents. Arch Gen Psychiatry 2004; 61:577–584
23.
Rosselló J, Bernal G: The efficacy of cognitive-behavioral and interpersonal treatments for depression in Puerto Rican adolescents. J Consult Clin Psychol 1999; 67:734–745
24.
Schramm E, Zobel I, Dykierek P, et al: Cognitive behavioral analysis system of psychotherapy versus interpersonal psychotherapy for early-onset chronic depression: a randomized pilot study. J Affect Disord 2011; 129:109–116
25.
Bridge JA, Iyengar S, Salary CB, et al: Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007; 297:1683–1696
26.
Hetrick SE, McKenzie JE, Coz GR, et al: Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database Syst Rev 2012; 11:CD004851
27.
March J, Silva S, Petrycki S, et al: Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004; 292:807–820
28.
March JS, Silva S, Petrycki S, et al: The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry 2007; 64:1132–1143
29.
Poznanski E, Mokros H: Children’s Depression Rating Scale–Revised (CDRS-R). Los Angeles, WPS, 1995
30.
Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 218–222
31.
Curry J, Rohde P, Simons A, et al: Predictors and moderators of acute outcome in the Treatment for Adolescents With Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 2006; 45:1427–1439
32.
March J, Silva S, Curry J, et al: The Treatment for Adolescents With Depression Study (TADS): outcomes over 1 year of naturalistic follow-up. Am J Psychiatry 2009; 166:1141–1149
33.
Goodyer IM, Dubicka B, Wilkinson P, et al: A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors: the ADAPT trial. Health Technol Assess 2008; 12:iii–iv, ix–60
34.
Goodyer I, Dubicka B, Wilkinson P, et al: Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial. BMJ 2007; 335:142–149
35.
Gowers SG, Harrington RC, Whitton A, et al: Brief scale for measuring the outcomes of emotional and behavioural disorders in children. Health of the Nation Outcome Scales for Children and Adolescents (HoNOSCA). Br J Psychiatry 1999; 174:413–416
36.
Wilkinson P, Dubicka B, Kelvin R, et al: Treated depression in adolescents: predictors of outcome at 28 weeks. Br J Psychiatry 2009; 194:334–341
37.
Brent D, Emslie G, Clarke G, et al: Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 2008; 299:901–913
38.
DeFilippis M, Wagner KD: Management of treatment-resistant depression in children and adolescents. Paediatr Drugs 2014; 16:353–361
39.
Fox CL, Butler I: Evaluating the effectiveness of a school-based counselling service in the UK. Br J Guid Counc 2009; 37:95–106
40.
Clarke GN, Hornbrook M, Lynch F, et al: A randomized trial of a group cognitive intervention for preventing depression in adolescent offspring of depressed parents. Arch Gen Psychiatry 2001; 58:1127–1134
41.
Horowitz JL, Garber J: The prevention of depressive symptoms in children and adolescents: a meta-analytic review. J Consult Clin Psychol 2006; 74:401–415
42.
McCarty CA, Violette HD, Duong MT, et al: A randomized trial of the Positive Thoughts and Action program for depression among early adolescents. J Clin Child Adolesc Psychol 2013; 42:554–563
43.
Johnstone J, Rooney RM, Hassan S, et al: Prevention of depression and anxiety symptoms in adolescents: 42 and 54 months follow-up of the Aussie optimism program-positive thinking skills. Front Psychol 2014; 5:364
44.
Garber J, Clarke GN, Weersing VR, et al: Prevention of depression in at-risk adolescents: a randomized controlled trial. JAMA 2009; 301:2215–2224
45.
Beardslee WR, Brent DA, Weersing VR, et al: Prevention of depression in at-risk adolescents: longer-term effects. JAMA Psychiatry 2013; 70:1161–1170
46.
Asarnow JR, Jaycox LH, Duan N, et al: Effectiveness of a quality improvement intervention for adolescent depression in primary care clinics: a randomized controlled trial. JAMA 2005; 293:311–319
Information & Authors
Information
Published In
History
Published in print: Winter 2016
Published online: 14 January 2016
Authors
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBLogin options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).